An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who ...

A 4-year study of cataract surgeons found that access to an unmasked peer benchmarking dashboard, supported by a noncoercive, ...

For patients with allergic rhinitis and chronic rhinosinusitis, the addition of vidian neurectomy to endoscopic sinus surgery ...

Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide, ...

Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes ...

DENVER — Adding the weight-loss drug tirzepatide to the biologic ixekizumab significantly improved joint and skin outcomes in ...

SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained ...

Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Patients with locally advanced ...

An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in ...